Category Archives: Healthcare

Dr. Sheldon Marks Authors Definitive Medical Textbook on Vasectomy Reversal

Springer Publishing Releases First Comprehensive Medical Guide Written by Leading Specialist in Male Reproductive Restoration.

Tucson, AZ, USA — Dr. Sheldon H.F. Marks, founder of the International Center for Vasectomy Reversal (ICVR), has just released a new medical textbook that promises to be the foremost medical reference for vasectomy reversal. Published by Springer, “Vasectomy Reversal: Manual of Vasovasostomy and Vasoepididymostomy” is the first medical textbook to provide a comprehensive, start-to-finish manual of vasectomy reversal for physicians interested in learning the procedure.

Dr. Marks has been performing vasectomy reversals for 35 years and his clinic, the International Center for Vasectomy Reversal (ICVR), reports up to a 99.5 percent success rate. The procedure has been successfully performed on thousands of men, no matter how much time has passed since their original vasectomy. Dr. Marks is one of the few urologists with a practice dedicated to vasectomy reversal, and in his new “Vasectomy Reversal” textbook he provides detailed instructions, including master’s techniques, tips and tricks, and protocols for handling various complications. Dr. Marks’ textbook is expected to become the definitive resource on vasectomy reversal and will be used by universities and teaching hospitals around the world.

More than 50 million men worldwide have had a vasectomy, and each year about 50,000 males in the U.S. undergo the procedure. However, life circumstances change and many men regret their decision when they lose a child, remarry, or simply realize they want to have their own children. While the vasectomy procedure itself is simple and routine, reversing the procedure requires microsurgery to reconnect the necessary tubes and there are few urologists in the country who can perform the procedure.

“A microsurgical vasectomy reversal remains the most cost-effective approach for any couple to have their own children following a vasectomy, offering unlimited attempts at natural conception. Drawing from decades of experience performing successful vasectomy reversals, I have captured what I have learned in this new medical textbook, offering step-by-step instruction, including detailed discussions of various treatment options before, during, and after the procedure. This is the same material I have been sharing with colleagues in courses and lectures, gathered in a single volume.”

Dr. Marks is a recognized expert in urological microsurgical procedures and has developed several courses on vasectomy reversal. At a recent international meeting of the American Society of Reproductive Medicine (ASRM) Dr. Marks led a roundtable on vas to epididymal bypass surgery, as well as a Special Masters symposium about advanced tips and techniques for vas-to-vas connections, vas-to-epididymal bypass and redo salvage reversal. He also is the author of the ASRM andrology certification module on vasectomy reversals and has taught a post-graduate course on vasectomy reversals for more than 12 years.

“Vasectomy Reversal: Manual of Vasovasostomy and Vasoepididymostomy” is available from Springer publishing (http://www.springer.com) in either hardcopy or electronic book form. For more information, visit http://www.springer.com/us/book/9783030004545.

About Dr. Sheldon H.F. Marks
Dr. Sheldon Marks is an internationally recognized microsurgical specialist and has been performing vasectomy reversals since 1983. He is the founder of the International Center for Vasectomy Reversal, which has treated patients from all 50 states and more than 80 countries. Dr. Marks also is the inventor of the Marks Vas Cutting Forceps as well as a regular contributor to WebMD. He also is an Associate Clinical Professor in the Division of Urology at the University of Arizona College of Medicine and Adjunct Assistant Professor in the Department of Urology, Tufts University School of Medicine, New England Medical Center in Boston. Dr. Marks practices what he believes is the lost art of caring for the unique needs of each patient as part of the “dads again” family.

For more information, visit http://www.dadsagain.com.

Media contact:
Tom Woolf
Woolf Media & Marketing
(415) 842-7398
tomw@woolfmedia.com

Just For Diabetics Website Offers Hope for Pre-diabetics, Type 2 diabetics, and the Overweight

 

Research shows that the best time to take action to reverse pre-diabetes and type 2 diabetes is when you are at the stage of managing these conditions.

Vancouver, BC, Canada, 2018-Nov-06 — /REAL TIME PRESS RELEASE/ — November is world diabetes month. When people are diagnosed type 2 diabetic, the first line of defense is the use of prescription drugs in order to manage the diabetes. But what victims of pre-diabetes and type 2 diabetes are not aware of is that research performed by Just For Diabetics website founder, Ernest Quansah, shows that when patients are managing their pre-diabetes or type 2 diabetes, it is the best opportunity for them to reverse it and be weaned off the prescription drugs. The research results are evidence based. Many doctors and institutions now agree that this is the case. Recently, the University of British Columbia, in conjunction with Pharmasave, a drugstore chain, began offering obese people and type 2 diabetics a diet plan aimed at reversal of pre-diabetes and type 2 diabetes. The cost of their plan is $500 a month. The diet plan calls for no consumption of refined sugar, potatoes, fruit, fruit juices, sweet drinks of any kind, rice, bread, and consumption of cooked vegetables for lunch, cooked chicken breast for dinner and so on. Many of the participants are seniors, the overweight, or obese. After several thousand of dollars spent, many participants lose weight and their doctors take them off their diabetes drugs.

Quansah’s program includes a specialized diabetes exercise regime along with vitamin therapy and a carefully designed tasty menu cycle. He himself completely reversed his severe case of type 2 diabetes after compiling this program, which was the culmination of thorough research. This research included the advice of several physicians. Quansah, founder of Just For Diabetics and the author of Diabetics Journey says: “For several years, I have been educating people about how type 2 diabetes and pre-diabetes can be reversed through the program offered on my website. Now we see that one of Canada’s finest Universities and a drug store chain are doing the same.”

The website, justfordiabetics.com offers a free weight-loss program, a free diabetes reversal program, as well as an inexpensive paid program. The extensive program includes a full menu regime, exercise videos, tutorials, in addition to a cooking video demonstration, all for less than $180. Quansah wisely suggests that those on the program be monitored by their doctors.

Quansah’s research and findings have been published in the WebMD Diabetes magazine in the article “Secret recipe: How a Chef Cured His Type 2 Diabetes”, as well as on the WebMD website. There is hope for reversing pre-diabetes, type 2 diabetes (the type that does not require insulin injections,) and for overcoming being overweight.

“Misinformation about type 2 diabetes is rampant. For diabetics to heal, they need a complete change of attitude and way of thinking. This means, they should not just accept managing their condition, but rather, understand that they can be healed. Further, complacency about pre-diabetes leads to full-blown diabetes, which can lead to heart disease, blindness, liver failure, impotence, limb amputations and early death,” cautions Quansah.

Quansah has been asked to be guest speaker at the Diabetes and Healthcare Conference being held in Helsinki, Norway, in November 2018 and to be keynote speaker at the Diabetes Care Conference being held in Malaysia in May of 2019. His speech topic will include how to help diabetics heal and resultantly reduce healthcare costs.

“What makes me so convinced that type 2 diabetics can be reversed? It’s my own success story. There is no evidence found in any part of the world that shows that type 2 diabetes cannot be reversed. With this conviction behind me, I wanted to offer the same possibility to the countless victims of pre-diabetes, type 2 diabetes, and those who are overweight, through launching justfordiabetics.com. My personal success in being cured is documented in my autobiographical book, Diabetics Journeyand encapsulated by this chart,” says Quansah. (The chart showing the before and after results of Quansah’s blood sugar tests is given below.)

The numbers in this chart represent blood sugar count in millimoles per litre (mmol/L).

 

————————————————————————————

Ernest Quansah is a type 2 diabetes Lifestyle Strategist, diabetes educator, keynote speaker, and the author of Diabetics Journey. He is the founder of Just For Diabetics.

He is available for radio, press, and TV interviews, as well as speaking engagements.

Diabetics Journey ISBN-13: 978-0994767035

available at Amazon

Website: https://justfordiabetics.com/

Media Kit: https://justfordiabetics.com/media-kit/

Email: ernest@justfordiabetics.com

 

Breast Cancer Assistance Group’s ‘Pink Partners’ Promotion with Local Businesses Raises Funds for Breast Cancer Patients

One in eight local women will experience the physical and emotional ravages of breast cancer.

Monterey, CA, October 02, 2018 — One in eight local women will experience the physical and emotional ravages of breast cancer. Breast cancer has high financial costs and many breast cancer patients find themselves unable to work during treatments.

The Breast Cancer Assistance Group of Monterey County (BCAG), an all-volunteer organization of breast cancer survivors, provides need-based grants that help patients in active treatment with their basic living expenses.

In honor of October as National Breast Cancer Awareness Month, BCAG is partnering with local businesses to raise funds and awareness to enable BCAG to help local breast cancer patients experiencing financial hardship due to their diagnosis and treatment.

One hundred percent of every dollar donated through BCAG’s “Pink Partners” promotion with local businesses will go to help breast cancer patients with food, housing, utilities, transportation, and other daily-living costs. During the past year BCAG awarded more than $116,000 to 77 local women.

BCAG is encouraging the public to show their support for helping the local community by patronizing the following businesses, participating in their special events and purchasing “Pink Partner” merchandise.

For the third year Pebble Beach Resorts will be showing its support for BCAG by donating $1 from every glass of rosé wine and “October Rose” cocktail at the following restaurants and bars:

• Stillwater Bar & Grill

• The Tap Room

• The Bench

• The Terrace Lounge

• Gallery

• Peppoli at Pebble Beach

• Roy’s at Pebble Beach

• Sticks

• Stave Wine Cellar

• Traps

• Spanish Bay Lobby

Quail Lodge & Golf Club will once again join the global effort to raise awareness on breast cancer through its Quail in Pink initiative. This year all fundraising proceeds will be donated to BCAG. Details on special events, including the Quail in Pink Afternoon Tea, the Quail in Pink Drive for the Cause guided motoring rally and Horsepower Happy Hour, Signature Pretty in Pink Vodka Cocktail, Quail in Pink embroidered apparel and accessories, and other specialty items for sale in the Golf Shop, Edgar’s Restaurant and Waypoint Bar & Deck can be found by visiting Quail in Pink

Carmel Valley Athletic Club will throw its annual Party in Pink, on October 20th from 10:00 – 2:00 p.m. This is a club-wide event open to members and non-members that donates all of the proceeds to BCAG. Members and guests who donate $20 or more will receive their own “Party in Pink” merchandise and will be able to utilize the club for the rest of the day. In addition, The Refuge outdoor relaxation spa will donate 10% from all gift certificates purchased throughout the month of October and $5 for every Deluxe Admission purchased on October 20th.

McIntyre Vineyards will once again hold its popular “Barre, Boobs & Bubbles” class on Friday, October 19th from 5:00pm – 7:00pm in the McIntyre Tasting Room at The Crossroads in Carmel. The class will be taught by Arianne Bautista, owner of CarmelBarre. All proceeds will be donated to BCAG. Call McIntyre Vineyards at 831-626-6268 to register for the event. In addition, McIntyre will donate 15% of sales revenue for purchases of 2017 Rosé of Pinot Noir wine throughout the month of October.

Throughout the month of October Sur at the Barnyard in Carmel will be donating 20% of every dollar spent for lunch or dinner and 10% for Happy Hour to BCAG. Diners must bring in a special BCAG coupon to qualify. Coupons are available on the BCAG website: Sur Pink Partner Dining Coupon

About BCAG

BCAG is an all-volunteer, non-profit organization of breast cancer survivors who raise funds and awareness to improve the lives of local breast cancer patients and their families. BCAG provides basic living expenses grants (for food, rent, gas, utilities, etc.) that relieve some of the financial worry associated with breast cancer and allows women (and men) to focus on fighting their disease so they can again spend quality time with family and return to the local workforce. BCAG serves residents of Monterey County who are being treated by physicians located anywhere and residents of Monterey, San Benito or Santa Cruz counties who are being treated by Monterey County physicians.

Breast Cancer Assistance Group of Monterey County

(FEIN 91-1972448)

P. O. Box 221582

Carmel, CA 93922

Phone: (831) 649-6365

Fax: (866) 219-8561

Email: contact@bcagmc.org

http://www.bcagmc.org

Contact:

Marci Bracco Cain

Chatterbox PR

Salinas, CA 93901

(831) 747-7455

http://www.bcagmc.org

10th Annual Embracing Mental Health Wellness & Recovery Conference on October 2nd

A FREE one-day mental health conference and consumer art show in Salinas!

Salinas, CA, September 20, 2018 – This conference is designed to introduce useful tools to implement the innovative concepts of wellness & recovery. Participants also have the ability to view works of art created by consumers of mental health services. This is our 10th year of providing trainings and techniques that can be an asset on the road to recovery.

Check-in starts at 8:30 AM.

Trainer:

Bruce Anderson, MRA, Managing Partner at Community Activators, Inc.

“Stories Work! Using Stories for Helping, Community Outreach, and Advocacy”

The use of stories has always been a foundational practice in healing and advocacy conversations. Now, with mental health services expanding beyond clinical services and including recovery, housing, employment and other community based activities, it is necessary to re-evaluate how professionals, advocates, and the people they serve can use stories in additional ways. This training is designed for professionals, advocates, and peers who are interested in expanding their storytelling skills and using stories in new ways as they serve others.

Lunch will be provided.

6 CEUs will be provided.

Continuing Education Information:

To receive CE credits, participants must:

Attend the course in its entirety. Partial credit for partial attendance cannot be granted.

Sign-in and sign-out at the beginning and end of the day, respectively.

Complete and turn in an evaluation for the course.

Following successful completion of the course:

CE Certificates either will be:

Handed out at the end of the training or

E-mailed to participants within 2 weeks of the date of the training.

BBS Licensure:

Stories Work! Using Stories for Helping, Community, Outreach, and Advocacy meets the qualifications for 6.0 hours of Continuing Education credit for LMFTs, LCSWs, LPCCs, and/or LEPs as required by the California Board of Behavioral Sciences.

Monterey County Behavioral Health (MCBH) is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for LMFTs, LCSWs, LPCCs, and/or LEPs. MCBH {Provider Number 70472) maintains responsibility for this program/course and its content.

Contact Information:

Accommodations related to access or food:

Interim, Inc. Wellness Conference Committee: 831-800-7530 x400 or acorres@interiminc.org.

Concerns or Grievances

Carmen Torres, LMFT, Employment & Wellness Services Director at 831-800-7530 x401 or ctorres@interiminc.org

MCBH’s Policy regarding CE credits {Policy 207):

http://qi.mtyhd.org/index.php/ policies-and-procedures-2/

REGISTER TODAY

Interim, Inc.

Interim, Inc. is the only agency in Monterey County that provides affordable housing, residential treatment, social support, homeless outreach and support, family outreach, and supported education and employment services for adults who have serious mental illnesses.

Our mission is to provide services and affordable housing supporting members of our community with mental illness in building productive and satisfying lives.

We believe that housing, healing, and hope are a path to mental health.

P.O. Box 3222 Monterey, CA 93942 • 831-649-4522 • www.interiminc.org

Contact:

Marci Bracco Cain

Chatterbox PR

Salinas, CA 93901

(831) 747-7455

Home

The Home Care Bible Now Available for Entrepreneurs Starting Their Own Senior Care Business

Founder of A Better Solution Home Care Nursing, Inc., Shares Tips and Techniques for Operating a Successful Home Health Care Operation.

San Diego, CA, USA — The Home Care Bible is now available for entrepreneurs seeking to launch a successful business offering home care services to seniors. Written by Lia Smith-Pratt (http://liasmith.net), CEO of A Better Solution (ABS) Home Care & Nursing, The Home Care Bible shares her experience and business tips from more than 30 years in health care and 18 years at ABS providing home and nursing services to seniors.

According to the Family Caregiver Alliance there are more than 8.4 million American seniors that receive long-term care services annually, and 27 million seniors will need some form of care by 2050. As a result, the home care is currently a $93.4 billion industry growing at an annual rate of 3.4 percent. Since more than 90 percent of aging Americans are opting for home health care, so the need for independent home care providers continues to grow at a dramatic pace. The Home Care Bible was written specifically for nurses, therapists, and non-medical professionals seeking to become their own boss and establish their own senior care practice.

“After working with so many home care providers over the years I have seen all the mistakes as well as a variety of successes,” said Smith-Pratt. “To be a winner in home care you need to adopt the right mindset and know where to look for potential pitfalls that could sink your business. Although I originally wrote The Home Care Bible to help ABS franchise partners, the book contains valuable lessons for anyone considering entering the home senior care field.”

In The Home Care Bible, Smith-Pratt shares her tips and techniques to home senior care business owners in how to avoid costly mistakes and build a successful business. It also illustrates how to build a care business with a culture of integrity and dedication to the Spirit of Service.

The Home Care Bible is available in paperback from Amazon or online at http://liasmith.net.

About Lia Smith-Pratt
Lia Smith-Pratt is the author of several books, including “Spiritual Lessons for my Daughters” and “Smart Steps to Big Dreams.” She also is founder and CEO of A Better Solution (ABS) Home Care & Nursing, which has been providing quality home care to seniors for 18 years through its care and placement services and ABS franchisees. When she is not working as CEO of ABS Home Care Nursing, she shares her business insight and experience as a business coach and inspirational speaker.

Smith-Pratt makes her home in San Diego.

Media Contact:
Lia Smith-Pratt
619-585-9011
liasmith@cox.net

FINALLY, A REAL INNOVATION IN DENTAL CARE – THE ONLY DUAL MODE LIGHT THERAPY ELECTRIC TOOTHBRUSH LAUNCHES ON KICKSTARTER

Los Angeles, California, 2018-Mar-26 — /REAL TIME PRESS RELEASE/ — Bristl combines proven science of light therapy with sonic vibration to improve oral care. The company also offers a subscription service to replace brush heads, so having the best oral health is also convenient.

Available on Kickstarter on Monday, March 26th at 9am (PST)

The combination of Bristl’s features, convenience, and style make for true market disruption:

Gum Health
Visible Red light (620–750 nm in wavelength) has been clinically proven to heal gum tissue and prevent inflammation. The same technology is often used in skincare; Bristl is bringing it to the everyday tooth brushing routine.

Kill Bacteria
Visible blue light (450–495 nm in wavelength) has been clinically proven to kill and prevent oral bacteria that causes gingivitis and other gum disease. This safe and natural blue light is proven to be effective, and Bristl is proud to bring it to market.

Get Rid of Plaque
Bristl has three sonic vibration modes: regular, gentle, and off. Sonic vibration is recommended by dentists as it has the highest cleaning ability without damaging gums. The brush head is also particularly designed to reach in crack and crevices while letting light pass through the bristles.

A Few Stats
According to a study published in the Journal of Periodontology and Implant Science (Vol. 44: pp. 280-287), Bristl’s technology (even with only red light) was effective in achieving the following:

  • 86% reduction in bacteria that causes destruction of tooth supporting tissue
  • 117% improvement in PPD (Periodontal Pocket Depth) which indicates gum health
  • 80% improvement in CAL (Clinical Attachment Level) which is another metric for gum health

Why Us?
The Bristl Science team consists of a group of innovators and scientists looking to use advanced technology to improve everyday lives. While we of course wish to build a successful business, we are doing so responsibly; Bristl has committed to donating a percentage of every sale to America’s Toothfairy to provide underserved children with dental care. Whether a customer or an underserved child, we’re on a mission to maximize oral health everywhere.

This is just the beginning. The Bristl Science team will work tirelessly to innovate and build products that improve lives, maximize health, and promote good. The Bristl light therapy toothbrush is just the first step toward a healthier future.

Clinical backing, photos, founders quotes, and more information can be found in our Media Kit:
http://bit.ly/2HtKTJ8

Campaign Preview: https://www.kickstarter.com/projects/574806194/565862801?ref=450743&token=dbd4feaa

If you have any questions at all, fee free to give us a call or shoot us an email.

Engineer, Cofounder, Media Contact:

Billy Walker
billy@bristlscience.com
763-607-2889

New Published Evidence Reinforces the Importance of Device Choice in Asthma Control

Two new publications build on previous evidence that not all devices are equally effective in delivering asthma control.

Plattsburgh, NY, USA — A recent article in Pulmonary Pharmacology and Physiology[1] provides in vitro evidence that the AEROCHAMBER PLUS® FLOW-VU® valved holding chamber (or spacer) delivers aerosolized drug more effectively than other chambers, a view further supported in a new literature review published in Therapeutic Advances in Respiratory Disease.[2]

The use of spacers with Metered Dose Inhalers (MDIs) has become firmly established in the management of asthma and COPD, with guidelines such as the Global Initiative for Asthma (GINA)[3] recommending their use to reduce oropharyngeal deposition of drug and counter the common problem of poor inhaler technique. What is not established, however, is whether there are any meaningful differences between the devices. While GINA guidelines do indicate that not all are the same – a view echoed by the European Medicines Agency (EMA) recommendations,[4] which state that data for MDIs should be generated with a ‘specific named spacer’ – this view is not expressed in all guidelines. Two recent publications set out to address the impact of spacer design on drug delivery performance and look at potential implications for clinical use.

Four similarly sized chambers were compared ‘out of the box’ in terms of statistical equivalence with the gold standard AEROCHAMBER PLUS® chamber with respect to retention of drug particles within the device and the aerodynamic particle size distribution of the drug particles delivered. Only the AEROCHAMBER PLUS® FLOW-VU® chamber (Monaghan Medical Corporation) demonstrated an equivalent profile of dose retention and delivery versus the reference chamber. The Compact Space Chamber Plus† (Medical Developments), the OptiChamber Diamond† (Philips Respironics, Inc), and InspiraChamber† (Lupin Pharmaceuticals, Inc) devices all retained approximately twice as much drug, delivering around half the dose and showing non-equivalent performance compared with the AEROCHAMBER PLUS® FLOW-VU® chamber and reference chamber (pretreated AEROCHAMBER PLUS® chamber).

Lead author, Dr Sanjeeva Dissanayake, has recently published a literature review in Therapeutic Advances in Respiratory Disease, which provides further support for these findings. In considering the important attributes of such delivery devices, the review notes a shift in emphasis from chamber size and shape to other aspects, such as consistency of drug delivery, static charge reduction, valve performance, and factors optimizing facemask effectiveness (such as flexibility and seal). Despite the general lack of published clinical studies that confirm the therapeutic benefits of such differences, the AEROCHAMBER® ‘family’ of chambers has amassed an impressive body of clinical evidence. Most recently, a real-world database study[5] has demonstrated improved clinical benefits and reduced resource utilization use with the AEROCHAMBER PLUS® FLOW-VU® chamber versus other chambers in patients with asthma. A study specifically looking at the FLOW-VU® inhalation indicator has also shown benefits for carer confidence in dose delivery, and improved care-giver preference and quality of life.[6]

Dr Dissanayake commented, ‘The in vitro equivalence study results and the literature review findings provide strong support for the EMA guideline recommendations that data for MDIs should be generated with specific spacer devices, and further reinforce the view that superficially similar chambers should not automatically be considered to be interchangeable – even if superficially similar’.

About Monaghan Medical Corporation (MMC, USA)
MMC offers leading aerosol drug delivery devices and respiratory management products including AEROECLIPSE® II BAN, AEROCHAMBER PLUS® aVHC and the AEROBIKA® device exclusively in the United States. MMC’s strength lies in product development around core capabilities in mechanical design complimented by collaboration with a state-of-the-art aerosol research laboratory. MMC focuses on developing cost-efficient, outcome-based solutions for its customers. (http://www.monaghanmed.com)

About AEROCHAMBER® brand valved holding chambers (VHC), including the AEROCHAMBER PLUS® FLOW-VU® AVHC
Developed in 1983 to address the needs of asthma and COPD patients having difficulty in taking their MDI medications correctly, the AEROCHAMBER® brand of chamber has innovated continuously to improve patient ease of use and quality of life as well as clinical outcomes and healthcare system savings.

• The AEROCHAMBER® brand is the global leader of chambers, with safety and efficacy validated in numerous third party clinical evaluations amongst various patient populations; it is the chamber most recommended by leading MDI pharmaceutical companies.[7]

• AEROCHAMBER PLUS® FLOW-VU® chamber is designed to deliver the intended prescribed dose via the MDI, similar to using an MDI with perfect technique. An additional feature is the incorporation of the FLOW-VU® inspiratory indicator for the care-giver to observe effective inhalation. The FLOW-VU® indicator provides real time feedback confirming an effective inhalation and ensures that there are no leakages of ambient air into the space between facemask and face, that could prevent medication delivery altogether. (http://www.monaghanmed.com)

For clinical inquiries, please contact:
Dominic P. Coppolo, MBA, RRT, FAARC
Vice President Clinical Strategy and Development
Monaghan Medical Corporation
1-800-343-9071

Words or phrases accompanied by ® are trademarks and registered trademarks of Monaghan Medical Corporation or an affiliate of Monaghan Medical Corporation. † trademarks of respective company. © 2018 Monaghan Medical Corporation.

1. Dissanayake S, Nagel M, Falaschetti E, Suggett J. Are valved holding chambers (VHCs) interchangeable? An in vitro evaluation of VHC equivalence. Pulmonary Pharmacology & Therapeutics. 2018; 48:179-184 http://doi.org/10.1016/j.pupt.2017.10.005
2. Dissanayake S, Suggett J. A review of the in-vitro and in-vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu anti-static VHC. Therapeutic Advances in Respiratory Disease. 2018; 12. http://doi.org/10.1177/1753465817751346
3. Global Initiative for Asthma: Global strategy for asthma management and prevention, 2017 Available from: www.ginaasthma.org. 2017.
4. Dissanayake S. Application of the EU Guidelines for Pharmacokinetic Studies of Locally Acting Orally Inhaled Drug Products. Respiratory Drug Delivery 2010. Vol 12010:293-304.
5. Burudpakdee, C., Kushnarev, V., Coppolo, D. et al. Pulmonary Therapy. 2017; 3(2):283-96. http://doi.org/10.1007/s41030-017-0047-1
6. Ammari WG, Toor S, Chetcuti P, Stephenson J, Chrystyn H. Evaluation of asthma control, parents’ quality of life and preference between AeroChamber Plus and AeroChamber Plus Flow-Vu spacers in young children with asthma. The Journal of Asthma: Official journal of the Association for the Care of Asthma. 2015;52(3):301-307.
7. AeroChamber brand of holding chambers. Study Summary (September 2017). Available from: http://www.trudellmed.com/aerochamber-study-summary

Landmark Asthma Study Demonstrates Device Choice Determines Asthma Control

Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration.

Plattsburgh, NY, USA — Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration. Research has shown that even when using the same metered-dose inhaler (MDI), not all valved holding chambers perform equally well.[1]

A landmark real-world study involving more than 18,000 asthma patients has demonstrated superior asthma control with the AEROCHAMBER PLUS® FLOW-VU® antistatic Valved Holding Chamber (VHC) compared with other chamber devices.[2] According to the study, published in Pulmonary Therapy, use of the AEROCHAMBER PLUS® FLOW-VU® antistatic chamber resulted in delayed time to first exacerbation, fewer asthma-related emergency department visits, and lower exacerbation-related costs than control chambers.

Asthma is a common respiratory condition that affects an estimated 24.6 million people in the United States. Almost half of them, including nearly 3 million children, experience one or more asthma attack in a year.[3]

As opposed to systemic medications, inhalation is the recommended way to administer asthma medications because it directly targets the drug to the lungs while reducing potential side effects. Inhaled corticosteroids and bronchodilators administered by MDIs are the mainstay of long-term asthma treatment, the goals of which are to improve symptoms and prevent the occurrence of exacerbations.[4]

Poor inhaler operation by users is common, resulting in less of the delivered drug reaching the lungs. Instead, much of it is deposited on the back of the throat (oropharyngeal deposition) and then swallowed.[5] Research shows that between 28% and 68% of patients do not use inhalers well enough to benefit from prescribed medication.[6] In addition, 25% of costs associated with inhalers is wasted due to poor inhaler technique.[6]

Chambers are designed to reduce oropharyngeal deposition by changing the particle size distribution of the inhaled aerosol, and by holding the aerosol in the chamber until the patient is ready to inhale, which reduces the need for good coordination between inhalation and inhaler actuation.[7] Effectiveness of these devices can be adversely affected by the design, including the chamber electrostatic charge, a commonly reported cause of inconsistent medication delivery.[8]

Global respiratory guidelines recommend the use of chambers to improve MDI drug delivery.[4] American Thoracic Society and American Association for Respiratory Care Clinical Practice Guidelines state that the addition of a chamber is recommended and helpful.[9,10] Research also indicates that patients who use a chamber with an MDI have better asthma control than those using an MDI alone.[11]

In this new study, Dr. Chakkarin Burudpakdee (QuintilesIMS, Fairfax, VA, USA) and colleagues compared the effects of the antistatic AEROCHAMBER PLUS® FLOW-VU® aVHC and control chambers on treatment outcomes, resource use, and healthcare costs in a real-world asthma population.[2] More than 18,000 patients were included from an adjudicated claims database containing medical and pharmacy claims for more than 150 million U.S. health plan members.[2]

The analysis showed that among patients with at least 30 days of follow-up, those using the AEROCHAMBER PLUS® FLOW-VU® antistatic VHC experienced a delay in the time to first exacerbation and had fewer asthma-related emergency room visits. In addition, exacerbation-related costs were lower when compared to those using the control (non-antistatic) chambers.[2] A trend toward lower exacerbation rates per patient for the AEROCHAMBER PLUS® FLOW-VU® aVHC was sustained throughout the 12 months of the study.[2]

“This landmark study using a large volume of real-world evidence generated from thousands of patients shows the value of optimizing drug delivery in asthma management and further supports that chambers are not interchangeable,” said co-author Dominic Coppolo, MBA, RRT, FAARC, Vice President Clinical Strategy and Development. “The reduction in exacerbation incidents among users of the AEROCHAMBER PLUS® FLOW-VU® chamber is particularly notable because experiencing an exacerbation is a risk factor for future exacerbation events-and minimizing exacerbation risk is a key goal of treatment.”

“The European Medicines Agency recommended in 2009 that development of a MDI should include the testing of at least one specific, named chamber, and that any substitution must be supported by appropriate in vitro or clinical data demonstrating equivalence,” he said. “We presented laboratory data at the recent Respiratory Drug Delivery Europe meeting[2] that confirmed that not all chambers perform equally well with the same MDI, which underlines the importance of recognizing the impact and potential risks of substituting one device for another.”

About Monaghan Medical Corporation
Monaghan Medical Corporation (MMC) offers leading aerosol drug delivery devices and respiratory management products including AeroEclipse® II BAN, AeroChamber Plus® aVHC and the Aerobika® device exclusively in the United States. MMC’s strength lies in product development around core capabilities in mechanical design complimented by collaboration with a state-of-the-art aerosol research laboratory. MMC focuses on developing cost-efficient, outcome-based solutions for its customers. (http://www.monaghanmed.com)

About AEROCHAMBER® brand valved holding chambers, including the AEROCHAMBER PLUS® FLOW-VU® anti-static chamber
Developed in 1983 to address the needs of asthma and COPD patients having difficulty in taking their MDI medications correctly, the AEROCHAMBER® brand of chamber has innovated continuously to improve patient ease of use and quality of life as well as clinical outcomes and healthcare system savings.

• The AEROCHAMBER PLUS® valved holding chamber is the leading global chamber brand, with safety and efficacy validated in numerous third-party clinical evaluations among various patient populations. It is the chamber most recommended by leading MDI pharmaceutical companies.
• AEROCHAMBER PLUS® FLOW-VU® chamber is an antistatic chamber designed to deliver the intended prescribed dose via the MDI, similar to using an MDI with perfect technique. An additional feature is the incorporation of the FLOW-VU® inhalation indicator for the caregiver to observe effective inhalation. A recent study showed that caregiver quality of life improved almost four-fold when using the AEROCHAMBER PLUS® chamber with FLOW-VU® indicator versus the same chamber without the indicator.[12] The FLOW-VU® indicator provides real-time feedback confirming an effective inhalation and that there are no leakages of ambient air into the space between facemask and face, which could prevent medication delivery altogether. (http://www.monaghanmed.com/AeroChamber-Plus-Flow-Vu-aVHC2)

About the study
Data for more than 18,000 patients with an asthma diagnosis were analysed from the QuintilesIMS Real-World Data Adjudicated Claims Database (PharMetrics Plus) between 1/2010 and 8/2015-9,325 using the AEROCHAMBER PLUS® FLOW-VU® antistatic VHC and a propensity-matched comparison cohort of 9,325 non-antistatic VHCs. Exacerbation incident rates (IR), time to first exacerbation using Kaplan-Meier survival analysis, occurrence of exacerbations, and healthcare resource use and costs were compared.

• Exacerbation IR/100 person-days (95% CI) was significantly higher in the control device cohort than the antistatic chamber cohort (0.161 [0.150-0.172] vs.0.137 [0.128-0.147]); more patients in the antistatic chamber cohort remained exacerbation free.
• 4,293 patients in each cohort were followed up for (greater than or equal to)12 months, during which there was a trend for patients in the antistatic VHC group to be less likely (10-12%) to experience an exacerbation. Fewer patients using the antistatic VHC had an ED visit compared with those in the control group (10.8% vs. 12.4%).
• Exacerbation-related costs for the antistatic VHC cohort were 23%, 25%, 20%, and 12% lower than the control device cohort at 1, 6, 9, and 12 months, respectively.

For clinical inquiries, please contact:
Dominic P. Coppolo, MBA, RRT, FAARC
Vice President Clinical Strategy and Development
Monaghan Medical Corporation
1-800-343-9071

Words or phrases accompanied by ® are trademarks and registered trademarks of Monaghan Medical Corporation or an affiliate of Monaghan Medical Corporation. © 2017 Monaghan Medical Corporation.

References

1 Nagel MW, Suggett JA. Equivalence evaluation of valved holding chambers (VHCs) with albuterol pressurized metered dose inhaler (pMDI). Respiratory Drug Delivery Europe; April 25-28, 2017, 2017; Nice, France.

2 Burudpakdee C, Kushnarev V, Coppolo D, Suggett J. A retrospective study of the effectiveness of the AeroChamber Plus® Flow-Vu® Antistatic Valved Holding Chamber for asthma control. Pulmonary Therapy. 2017. http://doi.org/10.1007/s41030-017-0047-1. Accessed July 14.

3 Asthma Facts. United States Environmental Protection Agency. EPA-402-F-04-019. May 2017.

4 Global Initiative for Asthma: Global strategy for asthma management and prevention, 2017. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention Accessed November 2017.

5 Price D, Bosnic-Anticevich S, Briggs A, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respiratory Medicine. 2013;107(1):37-46.

6 Fink JB, Rubin BK. Problems with Inhaler Use: A Call for Improved Clinician and Patient Education. Respir Care 2005;50(10):1360-74.

7 Lavorini F, Fontana GA. Targeting drugs to the airways: The role of spacer devices. Expert opinion on drug delivery. 2009;6(1):91-102.

8 Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respiratory care. 2007;52(3):283-300.

9 Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal 2014 ;43:343-373.

10 Ari A, et al. Aerosol Delivery Device Selection for Spontaneously Breathing Patients:2012. Respir Care 2012;57(4):613- 626.

11 Levy ML, et al. Asthma patients’ inability to use a pressurized metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the Global Initiative for Asthma (GINA) strategy: a retrospective analysis. Prim Care Respir J. 2013; Dec;22(4):406-11.

12 Ammari WG, et al. Evaluation of asthma control, parents’ quality of life and preference between AeroChamber Plus and AeroChamber Plus Flow-Vu spacers in young children with asthma. J Asthma 2015; 52(3):301-7.

FED Publishing Releases New Book, “My Journey, A Victory Over Cancer Through Alternative Methods” by Valarie Hendriks

My Journey, A Victory Over Cancer Through Alternative Methods, by Valarie Hendriks, is a story about one courageous woman’s journey and victory over cancer through alternative methods.

Oakland Township, MI, USA — Valarie Hendriks’ My Journey, A Victory Over Cancer Through Alternative Methods is a book that will make you laugh, make you cry, inspire you and motivate you. However, most of all it will help you in battling one of the most dreaded diseases plaguing mankind, cancer.

Valarie Hendriks grew up in the Midwest part of the United States. After college she got a job in the Optical field and is currently working as a Manager and ABO Certified Optician. Along the way she got married to her spouse of twenty five years. Her hobbies are tennis, horseback riding and Ball Room Dancing. She competed in Ball Room Dancing and won several competitions over her career. Then one day she was diagnosed with cancer. At this point in her life she thought her entire world was falling apart. However, she was determined to defeat this dreaded disease.

Her book My Journey, A Victory Over Cancer Through Alternative Methods is a book that Valarie wrote that outlines how she beat cancer. In her book she provides all of the information that she learned through two years of research so that she could help other people in their battle against cancer without going through the trauma of traditional cancer treatments. Her book is uplifting, inspiring, and motivational. It will make you laugh and it will make you cry but most of all it could help you to defeat one of the most dreaded diseases in the world, the disease that we call cancer.

Genre – Cancer, Cure, Alternative Methods, Alternative Medicine, Cancer Cure, Inspiration, Treatment, Motivational

The ebook version of My Journey, A Victory Over Cancer Through Alternative Methods ISBN 9781506903477, published by First Edition Design Publishing (http://www.firsteditiondesignpublishing.com), is available on-line wherever ebooks are sold. The 194 page print book version, ISBN 9781506903460, and ISBN 9781506903453 hardback, are published by First Edition Design Publishing and distributed worldwide to online booksellers.

Media Contact:
Valarie Hendriks
+1(941)921-2607
monty-nbf@att.net

Significant Cost Reduction in COPD Care With Simple, Drug-free Device

Aerobika® OPEP device proves to be a cost-effective treatment option in the management of post-exacerbation COPD patients.

Plattsburgh, NY, USA — The Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device (Monaghan Medical Corporation) is a cost-effective treatment option in the management of COPD exacerbations, according to a study published October 20th in the International Journal of COPD.[1] This study, which used data from the published literature and national fee schedules to model the cost-effectiveness of the Aerobika® OPEP device, shows that it provides both clinical benefit and direct medical cost savings in a post-exacerbation care COPD population.

COPD is a major (and growing) source of morbidity, mortality and healthcare utilization, with hospitalization for acute exacerbations being the biggest cost driver.[2] Once a patient experiences an exacerbation, the risk of further exacerbation is increased two- to four-fold[3], and many patients experience two or three exacerbations every year.[4] As many as one in five patients discharged from hospital following an exacerbation are re-admitted within 30 days.[5]

The economic burden on the healthcare system associated with COPD is significant; in the US alone, the cost of COPD in 2010 was estimated to be US $50 billion; $30 billion in direct healthcare expenditure, with the remainder accounted for by indirect costs such as productivity losses and costs to families.[6] Approximately half of the direct costs could be accounted for by hospital care for COPD exacerbations,[6] which supports the GOLD guideline treatment goals of minimizing the negative impact of exacerbations and preventing recurrences.[2] Healthcare systems in many countries acknowledge the problem, and policies are now being put in place to try to address it; the US Medicare Hospital Readmission Reduction Program penalizes hospitals for excess 30-day, all-cause readmissions after a hospitalization for an acute exacerbation of COPD.[7]

The Aerobika® OPEP device is a drug-free, handheld mechanical oscillating positive expiratory pressure (OPEP) device that has been designed to address the structural and functional challenges in the airways of patients with COPD. When the patient exhales through the device, it helps to expand the airways, loosen and expel mucus from the lungs and may also enhance drug deposition. It has been shown to improve lung function, exercise capacity and quality of life in COPD patients,[8] and a recent real-word study showed that the device reduced exacerbation rates in patients during the critical 30-day post-exacerbation period.[9] Using data from the latter study to provide real-world input, the authors of this current analysis showed cost savings ($553 per patient) and improved outcomes (equivalent to 6 fewer exacerbations per 100 patients per year) with the Aerobika® OPEP device compared with no OPEP/PEP use, and concluded that the device provides cost-effective treatment for post-exacerbation COPD patients.

The authors also used various scenarios to investigate the likelihood of the benefit continuing over a full year, and predicted further clinical and cost benefits (21 exacerbations per 100 patients per year; cost savings of $1,952 per patient). Author Dominic Coppolo, MBA, RRT, FAARC, Vice President Clinical Strategy and Development noted, “Our model provides evidence of clinical and cost benefits of the Aerobika® OPEP device in that critical 30-day period following an exacerbation. Given the high burden of COPD – in particular, costs relating to exacerbations – in the US population, we would expect that even a small benefit would have a significant impact on the healthcare system”. He went on to say that, although further studies would be needed to validate the long-term effectiveness, these data also give a good indication that the benefits will be sustained with long-term use.

“With the increasing pressure to improve care and reduce hospital admissions, the previously-published real-world study showing exacerbation reductions in the critical 30-day post exacerbation period gave us useful insights into the benefits of integrating the Aerobika® OPEP device into standard clinical practice”, noted Dr Jason Suggett (Group Director of Global Science and Technology, TMI). “This new analysis now gives us clear evidence that such clinical benefits would be translated into cost-effectiveness in this post-exacerbation population. In addition, new data presented at CHEST 2017 demonstrating that the generation of the proprietary pressure/oscillation pattern of the Aerobika* device efficiently generates oscillations throughout a high percentage of each exhaled breath, and with consistently high pressure amplitudes. The Aerobika* device demonstrated efficient and effective performance related to therapeutic effectiveness nearly twice that of other devices tested.”[10]

About Monaghan Medical Corporation (MMC, USA)
MMC offers leading aerosol drug delivery devices and respiratory management products including AeroEclipse® II BAN, AeroChamber Plus® aVHC and the Aerobika® device (http://www.monaghanmed.com/aerobika) exclusively in the United States. MMC’s strength lies in product development around core capabilities in mechanical design complimented by collaboration with a state-of-the-art aerosol research laboratory. MMC focuses on developing cost-efficient, outcome-based solutions for its customers.

About the Aerobika® device
The Aerobika® OPEP device (http://www.monaghanmed.com/Aerobika-OPEP) is a hand-held, robust, easy-to-use, drug-free oscillating positive expiratory pressure (OPEP) device designed to help expel mucus from the lungs, expand airways and enhance drug deposition. When the patient exhales through the device, intermittent resistance creates a unique pressure-oscillation dynamic, which expands the airways, helps expel the mucus to the upper airways where it can be coughed out. The Aerobika® OPEP device is designed to function independent of angle of use or flow rate, and allows for a direct aerosol pathway for patients using a nebulizer for medication delivery. The Aerobika® OPEP device has been shown to significantly improve forced vital capacity (FVC), 6-min walk distance (6MWD), and St. George’s Respiratory Questionnaire (SGRQ) score in COPD patients.[8] The Aerobika® OPEP device is available in the US via Monaghan Medical Corporation (http://www.monaghanmed.com), and in Canada, Mexico, and select European countries including the UK and Germany through Trudell Medical International (http://www.trudellmed.com).

About the study
A one-year Markov model was used to estimate the cost-effectiveness of the Aerobika® OPEP device in patients who had experienced an exacerbation in the previous month, or a post-exacerbation care population, with input data from the published literature and national fee schedules. Using a base-case assumption that the benefit of the Aerobika® OPEP device would last 30 days, cost-savings ($553 per patient) and improved outcomes (ie, 6 fewer exacerbations per 100 patients per year) were demonstrated when compared with no OPEP/positive expiratory pressure use. Assuming a scenario with effect beyond the conservative 30 day time frame, the Aerobika® OPEP device continued to show benefit (21 exacerbations per 100 patients per year; cost savings of $1,952 per patient). One-way sensitivity analyses were conducted for all input variables, increasing or decreasing the effect by 20%, to determine the impact of change on costs and health effects; the results supported the robustness of the base-case conclusions.

For clinical inquiries, please contact:
Dominic P. Coppolo, MBA, RRT, FAARC
Vice President Clinical Strategy and Development
Monaghan Medical Corporation
1-800-343-9071

Words or phrases accompanied by ® are trademarks and registered trademarks of Monaghan Medical Corporation or an affiliate of Monaghan Medical Corporation. © 2017 Monaghan Medical Corporation.

1. Khoudigian S, Kowal S, Suggett J, D. C. Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of COPD exacerbations. International journal of chronic obstructive pulmonary disease. 2017;In Press.
2. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.
3. Khakban A, Sin DD, FitzGerald JM, et al. The Projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective. Am J Respir Crit Care Med. 2017;195(3):287-291.
4. Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J. 2011;37(4):784-790.
5. Guerrero M, Crisafulli E, Liapikou A, et al. Readmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study. PLoS One. 2016;11(3):e0150737.
6. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235-245.
7. Shah T, Press VG, Huisingh-Scheetz M, White SR. COPD Readmissions: Addressing COPD in the Era of Value-based Health Care. Chest. 2016;150(4):916-926.
8. Svenningsen S, Paulin GA, Sheikh K, et al. Oscillatory Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease. COPD. 2016;13(1):66-74.
9. Burudpakdee C, Seetasith A, Dunne P, et al. A real-world study of 30-day exacerbation outcomes in chronic obstructive pulmonary disease (COPD) patient managed with Aerobika OPEP. Pulmonary Therapeutics. 2017.
10. Meyer A and Suggett J. A Laboratory Assessment into the Efficiency and Effectiveness of Different Oscillating Positive Expiratory Pressure Devices by Means of Patient Simulated Expiratory Waveforms. Presented at CHEST 2017.